Table 3 Associations between TTK protein expression and clinico-pathological indicators
Parameter | TTK (0–1) | TTK (2) | TTK (3) | P valuea |
|---|---|---|---|---|
Histological type | ||||
Ductal NOS | 147 (60.7%) | 67 (27.7%) | 28 (11.6%) | 0.0265 |
Lobular | 43 (76.8%) | 10 (17.9%) | 3 (5.4%) | |
Mixed ducto-lobular | 31 (88.6%) | 4 (11.4%) | 0 (0.0%) | |
Metaplastic | 9 (56.3%) | 7 (43.8%) | 0 (0.0%) | |
Tubular/cribiform | 8 (80.0%) | 2 (20.0%) | 0 (0.0%) | |
Other special types (incl mixed) | 37 (66.1%) | 14 (25.0%) | 5 (8.9%) | |
Overall grade | ||||
1 | 43 (76.8%) | 13 (23.2%) | 0 (0.0%) | <0.0001 |
2 | 162 (77.5%) | 41 (19.6%) | 6 (2.9%) | |
3 | 73 (47.7%) | 50 (32.7%) | 30 (19.6%) | |
Mitotic score | ||||
1 | 193 (79.8%) | 44 (18.2%) | 5 (2.1%) | <0.0001 |
2 | 33 (61.1%) | 18 (33.3%) | 3 (5.6%) | |
3 | 52 (43.0%) | 42 (34.7%) | 27 (22.3%) | |
Nuclear pleomorphism score | ||||
1–2 | 164 (75.2%) | 49 (22.5%) | 5 (2.3%) | <0.0001 |
3 | 115 (57.2%) | 55 (27.4%) | 31 (15.4%) | |
Tubule score | ||||
1 | 10 (76.9%) | 3 (23.1%) | 0 (0.0%) | NS |
2 | 52 (69.3%) | 20 (26.7%) | 3 (4.0%) | |
3 | 216 (65.5%) | 81 (24.5%) | 33 (10.0%) | |
Lymph node status | ||||
Positive | 77 (62.1%) | 41 (33.1%) | 6 (4.8%) | 0.0056 |
Negative | 81 (73.0%) | 18 (16.2%) | 12 (10.8%) | |
Tumor size | ||||
<2 cm | 112 (68.3%) | 40 (24.4%) | 12 (7.3%) | NS |
2–5 cm | 104 (66.2%) | 38 (24.2%) | 15 (9.6%) | |
>5 cm | 19 (61.3%) | 6 (19.4%) | 6 (19.4%) | |
Lymphovascular invasion | ||||
Absent | 214 (67.3%) | 77 (24.2%) | 27 (8.5%) | NS |
Present | 63 (63.6%) | 27 (27.3%) | 9 (9.1%) | |
Lymphocytic infiltrate | ||||
Absent | 119 (78.3%) | 28 (18.4%) | 5 (3.3%) | 0.0007 |
Mild | 115 (63.9%) | 47 (26.1%) | 18 (10.0%) | |
Moderate | 36 (53.7%) | 23 (34.3%) | 8 (11.9%) | |
Severe | 7 (41.2%) | 6 (35.3%) | 4 (23.5%) | |
Central scarring/fibrosis | ||||
Absent | 254 (67.7%) | 90 (24.0%) | 31 (8.3%) | NS |
Present | 25 (56.8%) | 14 (31.8%) | 5 (11.4%) | |
Tumor border | ||||
Infiltrative | 250 (69.1%) | 88 (24.3%) | 24 (6.6%) | 0.0003 |
Pushing (<50%) | 11 (36.7%) | 11 (36.7%) | 8 (26.7%) | |
Pushing (>50%) | 16 (64.0%) | 5 (20.0%) | 4 (16.0%) | |
Ki67 expression (20% threshold) | ||||
Low | 240 (71.6%) | 77 (23.0%) | 18 (5.4%) | <0.0001 |
High | 14 (25.9%) | 23 (42.6%) | 17 (31.5%) | |
Prognostic subgroups | ||||
HER2+ | 21 (51.2%) | 14 (34.1%) | 6 (14.6%) | <0.0001 |
HR+/HER2− (Ki67-high) | 6 (24.0%) | 13 (52.0%) | 6 (24.0%) | |
HR+/HER2− (Ki67-low) | 196 (76.0%) | 53 (20.5%) | 9 (3.5%) | |
TN (basal-like) | 23 (41.8%) | 20 (36.4%) | 12 (21.8%) | |
TN (non-basal) | 10 (71.4%) | 1 (7.1%) | 3 (21.4%) | |
